January 12, 2024 7:50am

 It’s also about pops and drops in “my” universe of cell and gene therapy sector

Pre-open Indications: 1 Sell into Strength, 3 Positive and 3 Negative Indications

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What RMi provides is a trusted source of share pricing intelligence.

Join me … in the NO spin zone!

Never leave an investor uninformed!

Remember that overnight action in a.m. futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

I make a commitment to provide need-to-know “facts in evidence” as an equity’s volatility is one tactical signal for stocks. My thesis is important in trying to distinguish the temporary from real pricing digression or progression.

I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

 

Friday: The pre-open Dow futures are DOWN -0.32% or (-120 points), the S&P futures are DOWN -0.08% or (-3.75 points) as the Nasdaq futures are DOWN -0.09% (-15 points)

Stock futures fell Friday as waiting for PPI “numbers”,

European markets were higher,

Asia Pacific markets fell

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies … https://www.regmedinvestors.com/articles/13283

Indexes closed mixed and “barely” with the Dow closed UP +12.72 points or +0.03%, the S&P closed DOWN -3.18 points or -0.07% while the Nasdaq closed barely UP +0.54 points or +0.00%

For the week so far, the Dow is up about +0.7%, while the S&P 500 +1.8% advance while the Nasdaq is up +3% through Thursday’s close.

Economic Data Docket: PPI, the producer price index;

  • Wholesale prices unexpectedly declining by 0.1% in December. The data follows the more widely followed consumer prices data Thursday, which came in modestly hotter than economists had forecasted, with prices up 0.3% on the month and 3.4% from a year ago.
  • Data that tracks selling prices received by domestic producers. 

 

Thursday, RegMed Investors (RMi) Closing Bell: “volatility rules. As new inflation number reignites throwing-off expectations displacing visibility of JPM2024 healthcare conference.” …  https://www.regmedinvestors.com/articles/13283

 

Q1/24: 1 holiday, 5 negative and 3 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Positive Indications:

Thursday’s, Wednesday, Tuesday Monday and last Friday’s closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Prime Medicine (PRME) closed down -$0.53 with a positive +$0.40 or +4.91% pre-open indication

Caribou Biosciences (CRBU) closed -$0.66 after Wednesday’s +$0.22 and Tuesday’s $0.00 with a positive +$0.02 or +0.38% pre-open indication

Ultragenyx Pharmaceuticals (RARE -$1.01 after Wednesday’s -$1.19 after Tuesday’s -$1.43 after Monday’s +$2.18 with a +$0.24 or +0.52% pre-open indication

 

Negative Indications:

Thursday’s, Wednesday, Tuesday, Monday and last Friday’s last closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Beam Therapeutics (BEAM) closed down -$1.00 after Wednesday’s -$0.88, Tuesday’s +$0.10 and Monday’s +$1.79 with a negative -$0.43 or -1.65% pre-open indication

Intellia Therapeutics (NTLA) closed down -$0.73 after Wednesday’s -$0.41 after Tuesday’s -$0.78 after Monday’s +$1.44 with a negative -$0.36 or -1.28% pre-open indication

Ionis Pharmaceuticals (IONS) closed up +$1.34 after Wednesday’s -$0.67, Tuesday’s +$0.56 and Monday’s +$1.62 with a negative -$0.36 or -0.67% pre-open indication

 

Sell-into-Strength Indication:

Thursday’s, Wednesday, Tuesday Monday and last Friday’s closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Sage Therapeutics (SAGE) closed up +$1.49 after Wednesday’s -$0.97, Tuesday’s +$1.27 and Monday’s +$3.63 with a positive +$0.23 or +0.86% pre-open indication

 

The BOTTOM LINE: it’s now the 2nd week of 2024, we have eaten more value that even almost exceeded the last months of 2023.

Momentum in the cell and gene therapy sector is connected with sentiment associated with the fall in yields, as I ask how long can this trend continue?

  • Answer … after we get beyond Q4 and FY23 reporting season as “runways” get measured, consensus and estimates get missed!

 

It was a tough start in 2024 as the cell and gene therapy sector as the JPM healthcare conference fizzles to an end.

  • For the next few weeks, if you're buying on weakness, you might be jumping onto a sinking ship even as … Q4 and FY23 earnings LPS (loss-per-share) are due even though some highlights were delivered to facilitate JPM presentations – there are consensus and beaten estimates to be reckoned!

 

My opinion from 12/29/23 ended with “my message of: Looking toward 2024 with one word – recalibration i.e., a change in the way you do or think about something – markets and the cell and gene therapy sector.”

  • I STILL believe the sector is headed into “correction” which means that investors should remain cautious as “our” universe skips into Q4 and 2023’s end earnings’ LPS (loss-per-share) reporting.

News, financings, Q4 earnings LPS (loss-per-share) and “runways” will be the under-current or headwind for January through March 2024. Pricing for gene therapies will continue to dominate share ascensions and downfalls!

  • It's also a good idea to take some profits, especially if you didn't do so in past sessions. <IBD>

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.